# Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

> **NCT06997367** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bharat Biotech International Limited** · enrollment: 164 (estimated)

## Conditions studied

- Tuberculosis (TB)

## Interventions

- **BIOLOGICAL:** MTBVAC
- **BIOLOGICAL:** BCG Sii

## Key facts

- **NCT ID:** NCT06997367
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997367, "Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06997367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*